BioSpace News Archive

Immunome, Inc., a biotechnology company focused on developing first-in-class and best-in-class targeted cancer therapies, announced that it has completed its previously announced merger with Morphimmune.

Akamis Bio, a clinical-stage oncology company using a proprietary Tumor-Specific Immuno-Gene (T-SIGn®) therapy platform to deliver novel immunotherapeutic proteins, biomolecules and transgene combinations to treat solid tumors, shared data today from a Phase 1 study of its adenovirus vector technology in combination with radiotherapy that showed improved response rates relative to expectations for radiation alone in patients with locally advanced rectal cancer.

Iambic Therapeutics Announces Close of Oversubscribed $100 Million Series B Financing to Advance AI-Discovered Therapeutics into Clinical Development and Enters Collaboration with NVIDIA.

Exscientia plc provided an update on its pipeline prioritisation strategy designed to further strengthen the Company’s focus, investment and infrastructure on programmes of greatest potential for differentiation and value creation.

Immunoglobulin National Society announced it is partnering with the Accreditation Commission for Health Care, an internationally recognized accreditation leader that develops solutions for healthcare providers worldwide.

Meitheal Pharmaceuticals, Inc. (“Meitheal”), a fully integrated generic injectables company based in Chicago, today announced it has expanded its portfolio of generic injectable products, through an asset purchase agreement by its parent company, Hong Kong King-Friend Industry Co., (HKF).

Atomwise, a leader in using AI for small molecule drug discovery, today announced the nomination of its first AI-driven development candidate focused on TYK2 inhibition and the appointment of Neely Mozaffarian, MD, PhD as Chief Medical Officer.

Ferring Pharmaceuticals today announced it will present two analyses of data for REBYOTA® (fecal microbiota, live – jslm), the first and only single-dose, FDA approved microbiome-based treatment to prevent recurrent Clostridioides difficile (C. diff) infection after antibiotic treatment.

IQVIA™ (NYSE:IQV), a leading global provider of advanced analytics, technology solutions and clinical research services to the life sciences industry, today announced a strategic collaboration with argenx to advance treatment to patients with rare autoimmune diseases through innovative and integrated technology-enabled pharmacovigilance (PV) safety services and solutions.

Equillium, Inc. (Nasdaq: EQ), a clinical-stage biotechnology company focused on developing novel therapeutics to treat severe autoimmune and inflammatory disorders, today announced that it will host a virtual analyst and investor day on Monday, October 16, 2023 at 9 a.m. PT / 12:00 p.m. ET.